Alnylam Pharmaceuticals Inc

NASDAQ:ALNY  
147.51
+1.21 (+0.83%)
Products

Alnylam Announces FDA Approval Of Amvuttra (Vutrisiran)

Published: 06/13/2022 23:28 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Announces FDA Approval of Amvuttra™ (vutrisiran), an Rnai Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis in Adults.
Amvuttra Met Primary and All Secondary Endpoints, With Significant Improvement in Polyneuropathy.company Expects to Launch Amvuttra in Early July.